NCT05051241View on ClinicalTrials.gov

A Study of GFH018 in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 30, 2019

Primary Completion Date

August 11, 2022

Study Completion Date

August 11, 2022

Conditions
Advanced Solid Tumor
Interventions
DRUG

GFH018

Subjects will receive GFH018 orally at different dose levels following twice daily, 14-day on/14-day off regimen. Other dose regimens, eg 7d-on/7d-off will also be considered to be explored when the safety/tolerability is confirmed.

Trial Locations (1)

Unknown

Shanghai East hospital, Shanghai

All Listed Sponsors
lead

Zhejiang Genfleet Therapeutics Co., Ltd.

INDUSTRY

NCT05051241 - A Study of GFH018 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter